About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Treatment of Type I Diabetes using Autologous Adipose Derived Mesenchymal Stem Cells Translated to Insulin Secreting Islet like Cell Aggregates

viagra cena heureka

viagra cena apoteka gedave.ro
Jaymesh M  Thadani, Anant Marathe, Shivani Vakodikar,  Prashant Kshatriya,  Dhwani Modi, Rajni Vyas, Bhaskar Vyas
Total Potential Cells (P) Ltd, 1st floor Parimal Majumdar Wada, Pratap road, Raopura. Vadodara-390001. Gujarat, India.
Corresponding Author:
Dr. Anant Marathe
Email: dranantmarathe@hotmail.com
Received: 08-MAR-2017 Accepted: 02-JUN-2017 Published Online: 05-JUL-2017
DOI: http://dx.doi.org/10.17659/01.2017.0064
Abstract
Background: A number of papers describe different stem cell lines as the presenting feature to treat diabetes. Case Report: We report a 21 year old female with type 1 diabetes mellitus who was treated with islet like cell aggregates (ICAs) translated from autologous adipose derived mesenchymal stem cells (ADMSCs). Half of the total count of autologous adipose-derived stromal vascular fraction (AD-SVF) was injected intramuscularly. The other half was purified to ADMSCs and translated to ICAs and injected by intra-hepatic route. The patient showed remarkable decrease in her insulin requirement. No side effects were noted related to the treatment. Conclusion: The case study suggests AD-SVF and ADMSCs translated to ICAs is effective alternative strategy for the treatment of juvenile diabetes.
Keywords : Adioposity, Cell Line, Diabetes Mellitus, Mesenchymal Stomal Cells, Islets of Langerhans.
Article Options
FULL TEXT
ABSTRACT
PDF
PRINTER FRIENDLY VERSION
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share

Androxal Medication Case Reports Journal

Expanding our scope, the Journal now encompasses an intriguing subset of articles specifically targeting treatments and patient outcomes related to the medication Androxal. This medication, primarily used in the treatment of male infertility, has shown unique potentials in diverse patient scenarios. Our studies with Androxal have given us an abundance of case reports, which demonstrate the multifaceted impact of this medication across therapeutic areas. This nuanced pharmaceutical perspective adds a fresh dimension to our regular case reports. Articles will reveal effective management processes, pinpointing how Androxal has proven beneficial where other treatments may have failed. In addition, the focus on Androxal will highlight instances of challenging or unexpected outcomes, where the medication may have interacted uniquely with the patient's unique biological system or interplayed with other treatments. As we forge ahead with this significant addition, we anticipate that our detailed case reports on Androxal will provide invaluable insights to both practitioners and patients navigating their medical journey with this medication.

© 2011 Journal of Case Reports
Last updated on Dec 04, 2024